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Background. Bisphenol A (BPA) is detected in the urine of >95% of US adults. Recent evidence from population-based studies
suggests that BPA is associated with individual components for metabolic syndrome (MetS). However, no previous study has
examined the direct association between BPA and MetS. Methods. We examined 2,104 participants from the National Health and
Nutrition Examination Survey 2003–2008. The main outcome was the presence of MetS (n = 741). Results. Increasing levels
of urinary BPA were positively associated with MetS, independent of confounders such as age, gender, race/ethnicity, smoking,
alcohol intake, physical activity, and urinary creatinine. Compared to tertile 1 (referent), the multivariable adjusted odds ratio
(95% confidence interval) of MetS in tertile 3 was 1.51 (1.07–2.12); P-trend was 0.02. Conclusions. Urinary BPA levels are positively
associated with MetS, in a representative sample of US adults and independent of traditional risk factors for MetS. Future,
prospective studies are needed to confirm our findings.
1. Introduction
According to national biomonitoring surveys conducted
by the Centers for Disease Control and Prevention, the
plasticizer, bisphenol A (BPA), is present in the urine of
more than 95% of US adults [1, 2]. BPA is an endocrine
disruptor with estrogen-like effects. Studies based on animal
models suggest that BPA exposure is associated with insulin
resistance and weight gain. Previous studies including those
from our group [3–5] suggest that higher BPA exposure is
related to individual components of the metabolic syndrome
(MetS) including hypertension [4, 6], diabetes mellitus [3, 7–
9], insulin resistance [10], and obesity [5, 8, 11]. However,
to our knowledge, there are no prior studies examining the
association between BPA exposure and MetS in humans. In
this context, we hypothesized that higher levels of BPA are
independently associated to higher likelihood of MetS. We
examined the association between urinary levels of BPA and
MetS in the National Health and Nutrition Examination Sur-
vey 2003–2008 (NHANES), a large nationally representative
multiethnic sample of US adults.
2. Methods
The current study is based on data from NHANES 2003–
2008 [12–14]. In brief, the NHANES survey included a
stratified multistage probability sample representative of the
civilian noninstitutionalized US population. Subjects signed
a consent form before their participation, and approval was
obtained from the Human Subjects Committee in the U.S.
Department of Health and Human Services [12–14].
The current study sample consisted of participants
aged ≥18 years among whom urinary BPA was available
(N = 5, 231). We further excluded subjects with missing
data on waist circumference, fasting serum glucose, serum
triglycerides, serum high-density lipoprotein (HDL) for
the definition of MetS, and other covariates used in our
multivariable models. The final sample for the analysis
comprised of 2,104 participants (51.0% women), of which
741 had MetS. Subjects who were excluded due to missing
covariates were in general similar to the final study sample
in terms of age, sex, race/ethnicity, smoking status, alcohol
intake, and moderate physical activity (see the Appendix).
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Rigorous procedures with quality control checks were
used in blood and urine collection, and details about these
procedures are available online [12–14]. Serum glucose,
triglycerides, and HDL were measured enzymatically in
the morning session (fasting sample) at the University of
Missouri Diagnostic Laboratory. Seated systolic and diastolic
blood pressures were measured using a mercury sphygmo-
manometer according to the American Heart Association
and Seventh Joint National Committee (JNC7) recommen-
dations [15]. Up to 3 measurements were averaged for
systolic and diastolic pressures. Urinary creatinine analysis
was based on the Jaffe reaction and using CX3 analyzer.
Previous measures of BPA in biological matrixes involved
techniques such as gas chromatography or high perfor-
mance liquid chromatography [16]. To achieve enhanced
sensitivity and selectivity over previous methods, in the
current NHANES, measures of environmental phenols were
derivatized to alkyl or acyl derivatives before gas chromatog-
raphy/mass spectrometry analysis [17–19]. The lower limit
of detection for BPA concentrations was 0.36 ng/mL.
MetS was defined based on the revised Adult Treatment
Panel III (ATP III) guidelines [20] and included the fol-
lowing criteria: (1) abdominal obesity (waist circumference:
≥102 cm in men and ≥88 cm in women), (2) hyperten-
sion (systolic blood pressure ≥130 mm of Hg, diastolic
blood pressure ≥85 mm of Hg, use of medications for
elevated blood pressure), (3) elevated serum triglycerides
(≥150 mg/dL), (4) glucose intolerance (fasting serum glu-
cose≥100 mg/dL, medications for diabetes), and (5) reduced
HDL (<40 mg/dL for men and <50 mg/dL for women).
Participants positive for 3 or more of the 5 measured
components were considered to have MetS.
3. Statistical Analysis
Urinary BPA was categorized into tertiles (<1.4 ng/mL, 1.4–
3.4 ng/mL, and >3.4 ng/mL). We hypothesized that high BPA
levels are associated with MetS. The odds ratio [(OR) (95%
confidence interval (CI)] of MetS for BPA was calculated
by taking the lowest tertile (tertile1) as the referent, using
multivariable logistic regression models. We used two mod-
els: the age and sex-adjusted model and the multivariable
model, additionally adjusting for race/ethnicity, annual
household income, smoking status, alcohol intake, moderate
physical activity, and urinary creatinine (mg/dL). Trends in
the OR of MetS across increasing urinary BPA categories
were determined by modeling BPA as an ordinal variable.
Sample weights that account for the unequal probabilities of
selection, oversampling, and nonresponse were applied for
all analyses using SAS (version 9.3; SAS Institute, Cary, NC,
USA) and SUDAAN software; standard errors (SEs) were
estimated using the Taylor series linearization method.
4. Results
Table 1 shows the characteristics of the whole cohort.
Participants with higher levels of BPA were more likely to
be of non-Hispanic White race/ethnicity, currently smoking,
have higher levels of alcohol intake, higher triglycerides,
lower HDL, and higher urinary creatinine levels.
In Table 2, we examine the association between BPA
and MetS. Overall, increasing levels of BPA were associated
with MetS in both the age and sex-adjusted model and
the multivariable model, where we additionally adjusted
for race/ethnicity, smoking status, alcohol intake, annual
household income, moderate physical activity, and urinary
creatinine levels; P values for trend were also significant (P-
trend = 0.02).
5. Discussion
In a representative sample of US adults, we found that
increasing levels of urinary BPA were positively associated
with MetS. The observed association was found to be
independent of confounding factors such as age, gender,
race/ethnicity, smoking, alcohol intake, moderate physical
activity levels, and urinary creatinine. To our knowledge, our
study is the first report on a positive association between BPA
and MetS in humans.
BPA is a constituent monomer in polycarbonate plastics,
used extensively in the manufacture of several consumer
grade products including food packaging, bottled water
and the lining of canned foods [21]. Recent studies have
documented that over 95% of the US population have
measurable concentrations of BPA in their urine [1, 2].
Several lines of recent evidence suggest that our findings
of an association between BPA and MS are plausible.
Previous studies based on animal models provide evidence
towards both the endocrine disrupting and estrogen-like
effects of BPA and suggest that BPA exposure is related to
increased insulin resistance [22] and, therefore, has a role
in weight gain and the development of obesity [5, 8, 23].
In an experimental study on human tissue explants, Hugo
et al. found that increasing levels of BPA inhibit the release
of the beneficial lipid modulating hormone adiponectin,
implicating BPA in the development of insulin resistance
and MetS [24]. Furthermore, BPA was also associated with
known MetS risk factors such as hypertension [4, 6] and
diabetes [3, 7–9] in previous studies.
The main strengths of our study include its nationally
representative sample, use of rigorous study methods to
collect the data, and the availability of extensive data on
confounders [12–14]. The main study limitation is that
the current study is cross-sectional in nature, therefore,
making it impossible to draw cause effects in the observed
associations. Another concern to our observed association
between BPA levels and MetS is the potential confounding
role of diet. It has been shown that majority of BPA exposure
in humans is dietary (e.g., the modern Western fast-food diet
and drinking canned/bottled sodas) [25], and the same types
of diet have been shown to be associated with MetS [26].
Also, recent reports on the pharmacokinetics of BPA suggest
that in humans most of BPA is metabolized before it reaches
the systemic circulation [27, 28]; therefore, the observed
BPA-MetS association may be noncausal and confounded by
unhealthy diet.
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Table 1: Characteristics of the study population from NHANES 2003–2008a.
Characteristics Tertile 1 (N = 695) Tertile 2 (N = 704) Tertile 3 (N = 705) P value
Age (years) 48.29 ± 0.74 45.24 ± 0.73 42.26 ± 0.64 <0.0001
Female (%) 381 (56.3) 338 (48.4) 343 (48.4) 0.03
Race/ethnicity (%)
Non-Hispanic Whites 367 (75.3) 357 (71.8) 314 (67.5)
0.02
Non-Whites 328 (24.7) 347 (28.2) 391 (32.4)
Smoking status (%)
Never smoker 351 (50.8) 338 (49.9) 309 (44.5)
0.05
Former smoker 186 (26.8) 177 (24.5) 147 (23.8)
Current smoker 121 (20.2) 141 (22.5) 161 (26.4)
Missing 37 (2.3) 48 (3.1) 88 (5.2)
Alcohol intake (%)
Nondrinker 291 (31.8) 272 (33.1) 312 (35.4)
<0.0001Moderate drinker 278 (49.7) 249 (39.7) 221 (36.2)
Heavy drinker 126 (18.4) 183 (27.2) 172 (28.4)
Annual household income
<$20,000 129 (10.8) 133 (12.7) 160 (15.7)
0.02
$20,000–$54,999 261 (32.4) 269 (35.9) 287 (38.8)
≥55,000 257 (51.8) 250 (45.2) 224 (40.9)
Missing 48 (4.9) 52 (6.2) 34 (4.6)
Moderate physical activity (%) 233 (42.4) 251 (40.1) 265 (39.9) 0.69
Waist circumference (cm) 95.97 ± 0.74 97.81 ± 0.85 97.86 ± 0.89 <0.0001
Systolic blood pressure (mm of Hg) 120.56 ± 0.76 120.76 ± 0.60 119.58 ± 0.81 <0.0001
Diastolic blood pressure (mm of Hg) 70.17 ± 0.66 69.65 ± 0.57 69.48 ± 0.54 <0.0001
Serum triglycerides (mg/dL) 129.61 ± 3.84 138.16 ± 5.88 145.81 ± 5.32 <0.0001
Serum HDL (mg/dL) 57.19 ± 0.86 54.86 ± 0.81 52.20 ± 0.65 <0.0001
Serum glucose (mg/dL) 102.78 ± 1.22 102.64 ± 1.02 104.85 ± 1.58 <0.0001
Urinary creatinine (mg/dL) 85.03 ± 2.57 132.83 ± 3.07 175.80 ± 4.14 <0.0001
Metabolic Syndrome (%) 30.0 34.9 38.9 0.01
a
Data presented are number (percentages) or mean values ± standard error (SE), as appropriate for the variable.
Table 2: Association between bisphenol A and metabolic syndrome.
Bisphenol A (ng/mL)
Sample size Age, sex-adjusted OR Multivariable-adjusted OR
(% MetS) (95% CI)a (95% CI)a,b
Tertile 1 (<1.40) 695 (30.0) 1 (referent) 1 (referent)
Tertile 2 (1.40–3.40) 704 (34.9) 1.26 (0.95–1.68) 1.24 (0.93–1.65)
Tertile 3 (>3.40) 705 (38.9) 1.53 (1.09–2.15) 1.51 (1.07–2.12)
P-trend 0.01 0.02
a
OR (95% CI): odds ratio (95% confidence interval).
bAdjusted for age (years), gender (male, female), race/ethnicity (non-Hispanic Whites, non-Hispanic Blacks, Mexican Americans, and others), annual
household income, smoking (never, former, and current), alcohol intake (nondrinker, moderate drinker, and heavy drinker), moderate physical inactivity
(absent, present), and urinary creatinine (mg/dL).
Previous studies have suggested the inclusion of several
additional markers associated with insulin resistance and
increased cardiovascular risk, such as hyperuricemia [29],
nonalcoholic fatty liver disease [30], polycystic ovary syn-
drome [31], and hypogonadism [32] towards the assessment
of MetS. However, in the current study, our definition of
MetS is based on the revised ATP III guidelines [20], which
do not include these markers. Since BPA may be positively
associated with many of these markers, using the ATP
III definition for MetS may have attenuated our observed
association. Future studies on BPA and MetS should try to
also incorporate these newly suggested markers of MetS to
study the true association.
In conclusion, we found that in a nationally represen-
tative sample of US adults, higher exposure to BPA was
positively associated with MetS independent of confounding
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Table 3: Comparison of those who were included the final analytic sample to those who were excluded due to missing dataa.
Characteristics Final analytic sample (N = 2,104) Missing data (N = 3,127) P value
Age (years) 45.3 ± 0.5 45.4 ± 0.4 <0.0001
Female (%) 1,062 (51.0) 1,625 (52.1) 0.54
Race/ethnicity (%)
0.29Non-Hispanic Whites 1,038 (71.6) 1,486 (70.0)
Non-Whites 1,066 (28.4) 1,641 (30.0)
Smoking status (%)
0.64
Never smoker 998 (48.4) 1,497 (49.9)
Former smoker 510 (25.0) 713 (23.0)
Current smoker 423 (23.0) 645 (23.3)
Missing 173 (3.5) 271 (3.7)
Alcohol intake (%)
0.10
Nondrinker 875 (33.4) 1,448 (36.4)
Moderate drinker 748 (41.9) 1,022 (39.0)
Heavy drinker 481 (24.6) 657 (24.6)
Annual household income
0.02
<$20,000 422 (13.0) 733 (15.9)
$20,000–$54,999 817 (35.6) 1,215 (35.7)
≥55,000 731 (46.0) 942 (42.0)
Missing 134 (5.2) 237 (6.3)
Moderate physical activity (%) 749 (40.8) 1,075 (38.3) 0.18
a
Data presented are number (percentages) or mean values ± standard error (SE), as appropriate for the variable.
factors such as age, gender, race/ethnicity, smoking, alcohol,
moderate physical activity and urinary creatinine. If con-
firmed in future prospective studies, reducing environmental
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